Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer.
Boston, United States. In J Clin Oncol, 01 Nov 2014
Therefore, we evaluated whether inclusion of plasma estradiol, estrone, estrone sulfate, testosterone, dehydroepiandrosterone sulfate, prolactin, and sex hormone-binding globulin (SHBG) improved risk prediction for postmenopausal invasive breast cancer (n = 437 patient cases and n = 775 controls not using postmenopausal hormones) in the Nurses' Health Study.
Protein tyrosine phosphatases as potential therapeutic targets.
Indianapolis, United States. In Acta Pharmacol Sin, 15 Oct 2014
This review summarizes recent findings on several highly recognized PTP family drug targets, including PTP1B, Src homology phosphotyrosyl phosphatase 2,(SHP2), lymphoid-specific tyrosine phosphatase (LYP), CD45, Fas associated phosphatase-1 (FAP-1), striatal enriched tyrosine phosphatases (STEP), mitogen-activated protein kinase/dual-specificity phosphatase 1 (MKP-1), phosphatases of regenerating liver-1 (PRL), low molecular weight PTPs (LMWPTP), and CDC25.
Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.
Illkirch-Graffenstaden, France. In Front Endocrinol (lausanne), Dec 2013
They act through five G-protein-coupled receptors and each group of peptide binds to and activates mostly one receptor: RF-amide related peptide group binds to NPFFR1, neuropeptide FF group to NPFFR2, pyroglutamylated RF-amide peptide group to QRFPR, prolactin-releasing peptide group to prolactin-releasing peptide receptor, and kisspeptin group to Kiss1R.
Does Kisspeptin Belong to the Proposed RF-Amide Peptide Family?
Seoul, South Korea. In Front Endocrinol (lausanne), Dec 2013
Because of the Arg-Phe (RF) sequence at its carboxyl terminus, KISS has been proposed to be a member of the RF-amide peptide family consisting of neuropeptide FF (NPFF), neuropeptide VF (NPVF), pyroglutamylated RF-amide peptide (QRFP), and prolactin-releasing hormone (PRLH).
Mutant prolactin receptor and familial hyperprolactinemia.
More papers using
Glasgow, United Kingdom. In N Engl J Med, Dec 2013
These symptoms were not associated with pituitary tumors or multiple endocrine neoplasia but were due to a heterozygous mutation in the prolactin receptor gene, PRLR, resulting in an amino acid change from histidine to arginine at codon 188 (His188Arg).